Federal health officials on Wednesday announced the launch of a new Trump administration initiative to cover up to $500 worth of hemp-derived products each year for eligible patients. The program being implemented by the Centers for Medicare & Medicaid Services (CMS) focuses largely on CBD but also allows a certain amount of THC in products.
“CMS is committed to innovation that meets patients where they are while maintaining strong safeguards and clinical oversight,” CMS Administrator Dr. Mehmet Oz said in a press release. “Under the president’s leadership, we’re expanding the tools available to improve patients’ health while generating important insights into how providers can use these tools safely and effectively in real-world care settings.”
President Donald Trump signed an executive order in December calling on the attorney general to finalize a rule federally rescheduling marijuana that also contained components to “improve access” to full-spectrum CBD products.
To that end, the new CMS hemp initiative “reflects the Administration’s broader efforts to expand access to innovative, patient-centered care,” the agency said. “It marks a meaningful step as CMS begins testing how emerging care tools can be integrated into coordinated care to improve outcomes and quality of life.”
CMS’s new Substance
Read full article on Marijuana Moment
